Vor Biopharma Balance Sheet Health
Financial Health criteria checks 3/6
Vor Biopharma has a total shareholder equity of $-1.5B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $205.4M and $1.7B respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$200.57m |
| Equity | -US$1.51b |
| Total liabilities | US$1.71b |
| Total assets | US$205.37m |
Recent financial health updates
We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully
Sep 11
We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate
Apr 08We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate
Dec 24Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely
Sep 10Recent updates
We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully
Sep 11Vor Biopharma: Chinese Win Sets The Direction, But There Is Still Much Uncertainty
Aug 13Calculating The Intrinsic Value Of Vor Biopharma Inc. (NASDAQ:VOR)
Jun 25We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate
Apr 08Vor Biopharma: Short On Cash, Too Much Uncertainty For Now
Feb 24We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate
Dec 24Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely
Sep 10We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate
May 24Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation
Dec 05Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?
Aug 18Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans
May 05Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?
Mar 13We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully
Oct 19Vor Bio appoints Eyal C. Attar as chief medical officer
Oct 12Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?
Jun 18Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans
Mar 05Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans
Aug 30Vor Biopharma: Targeted Therapies For Transplants
Jun 30We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate
May 10Financial Position Analysis
Short Term Liabilities: VOR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: VOR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: VOR is debt free.
Reducing Debt: VOR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VOR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VOR has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 22.8% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/14 16:02 |
| End of Day Share Price | 2025/09/12 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vor Biopharma Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Carter Gould | Barclays |
| Justin Walsh | B. Riley Securities, Inc. |